David C. McCaleb
President at McCaleb Associates, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marie Wesselhoft | F | - |
ZelosDx, Inc.
 ZelosDx, Inc. Electronic Equipment/InstrumentsElectronic Technology MSDx, Inc. provides novel biomarker tools for studying disease processes. It offers research and reference test products for multiple sclerosis research laboratories, clinical laboratory organizations, and specialty labs; point-of-care tests to the physicians providing care to the multiple sclerosis patients; and reagent kits to in-vitro diagnostic manufacturers. The firm provides blood test products for health care professionals and patients in the United States and internationally. The company was founded by Stephen Bassett, Allan Conger, Rick Gibson and Marie Wesselhoft in 2005 and is headquartered in Tucson, AZ. | 19 years |
| Michael Sember | M | - |
ZelosDx, Inc.
ZelosDx, Inc. Electronic Equipment/InstrumentsElectronic Technology MSDx, Inc. provides novel biomarker tools for studying disease processes. It offers research and reference test products for multiple sclerosis research laboratories, clinical laboratory organizations, and specialty labs; point-of-care tests to the physicians providing care to the multiple sclerosis patients; and reagent kits to in-vitro diagnostic manufacturers. The firm provides blood test products for health care professionals and patients in the United States and internationally. The company was founded by Stephen Bassett, Allan Conger, Rick Gibson and Marie Wesselhoft in 2005 and is headquartered in Tucson, AZ. | - |
| Conrad A. Plimpton | M | - |
ZelosDx, Inc.
ZelosDx, Inc. Electronic Equipment/InstrumentsElectronic Technology MSDx, Inc. provides novel biomarker tools for studying disease processes. It offers research and reference test products for multiple sclerosis research laboratories, clinical laboratory organizations, and specialty labs; point-of-care tests to the physicians providing care to the multiple sclerosis patients; and reagent kits to in-vitro diagnostic manufacturers. The firm provides blood test products for health care professionals and patients in the United States and internationally. The company was founded by Stephen Bassett, Allan Conger, Rick Gibson and Marie Wesselhoft in 2005 and is headquartered in Tucson, AZ. | - |
| Simranjcet Singh Nirh | M | - |
ZelosDx, Inc.
ZelosDx, Inc. Electronic Equipment/InstrumentsElectronic Technology MSDx, Inc. provides novel biomarker tools for studying disease processes. It offers research and reference test products for multiple sclerosis research laboratories, clinical laboratory organizations, and specialty labs; point-of-care tests to the physicians providing care to the multiple sclerosis patients; and reagent kits to in-vitro diagnostic manufacturers. The firm provides blood test products for health care professionals and patients in the United States and internationally. The company was founded by Stephen Bassett, Allan Conger, Rick Gibson and Marie Wesselhoft in 2005 and is headquartered in Tucson, AZ. | 19 years |
| Ramesh Chand Nayak | M | - |
ZelosDx, Inc.
ZelosDx, Inc. Electronic Equipment/InstrumentsElectronic Technology MSDx, Inc. provides novel biomarker tools for studying disease processes. It offers research and reference test products for multiple sclerosis research laboratories, clinical laboratory organizations, and specialty labs; point-of-care tests to the physicians providing care to the multiple sclerosis patients; and reagent kits to in-vitro diagnostic manufacturers. The firm provides blood test products for health care professionals and patients in the United States and internationally. The company was founded by Stephen Bassett, Allan Conger, Rick Gibson and Marie Wesselhoft in 2005 and is headquartered in Tucson, AZ. | - |
| Melita Ball | F | - |
ZelosDx, Inc.
ZelosDx, Inc. Electronic Equipment/InstrumentsElectronic Technology MSDx, Inc. provides novel biomarker tools for studying disease processes. It offers research and reference test products for multiple sclerosis research laboratories, clinical laboratory organizations, and specialty labs; point-of-care tests to the physicians providing care to the multiple sclerosis patients; and reagent kits to in-vitro diagnostic manufacturers. The firm provides blood test products for health care professionals and patients in the United States and internationally. The company was founded by Stephen Bassett, Allan Conger, Rick Gibson and Marie Wesselhoft in 2005 and is headquartered in Tucson, AZ. | - |
| Betty R. Weaver | F | - |
ZelosDx, Inc.
ZelosDx, Inc. Electronic Equipment/InstrumentsElectronic Technology MSDx, Inc. provides novel biomarker tools for studying disease processes. It offers research and reference test products for multiple sclerosis research laboratories, clinical laboratory organizations, and specialty labs; point-of-care tests to the physicians providing care to the multiple sclerosis patients; and reagent kits to in-vitro diagnostic manufacturers. The firm provides blood test products for health care professionals and patients in the United States and internationally. The company was founded by Stephen Bassett, Allan Conger, Rick Gibson and Marie Wesselhoft in 2005 and is headquartered in Tucson, AZ. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christopher Chai | M | 58 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
| Tricia Borga Suvari | F | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 11 years |
| Kenneth Lee | M | 76 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
| Andrew Wolff | M | 69 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 years |
| Jennifer Hodge | F | 55 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
| Bruce Philip Pritchard | M | 51 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 years |
| Michael T. Sweeney | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| Philip Wells | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
| David Banks | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| Lorenz Muller | M | 60 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 years |
| Anders Waas | M | 67 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
| Hsiao Lieu | M | 53 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Cam Gallagher | M | 54 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 12 years |
| Colin Hislop | M | 66 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Markus Jerling | M | 72 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| Huang I-Zu | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 6 years |
| Steven R. Schow | M | 74 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Paul J. Frohna | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 years |
| Whedy Wang | M | 60 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 9 years |
| Douglas T. Sheehy | M | 57 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 years |
| Anne Champsaur | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Lewis J. Stuart | M | 64 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
| Dan Spiegelman | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 11 years |
| Peter M. Strumph | M | 59 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 years |
| Kenneth F. Boehm | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| R. Greer | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Santo Costa | M | 78 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
| Costa G. Sevastopoulos | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Richard M. Lawn | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 14 years |
| Peter Hutt | M | 89 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
| Louis Yu | M | 73 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
| John Groom George | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Thomas Shenk | M | 77 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 years |
| George F. Schreiner | M | 74 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
| Brent Blackburn | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
| Michael M. Wick | M | 77 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 years |
| Joseph M. Davie | M | 84 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
| Huw Jones | M | 62 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | - |
| Karin Walker | F | 60 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 46 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David C. McCaleb
- Personal Network
